Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Prashant Manohar Gaikwad"'
Autor:
Niladri Das, Silima Subhasnigdha Tarenia, Souvik Saha, Prashant Manohar Gaikwad, Deep Kamlesh Hathi, Soumik Goswami, Arjun Baidya, Nilanjan Sengupta
Publikováno v:
Journal of the ASEAN Federation of Endocrine Societies, Vol 38, Iss 2 (2023)
Primary growth hormone (GH) resistance or growth hormone insensitivity syndrome, also called Laron syndrome, is a hereditary disease caused by mutations in the GH receptor or in the post-receptor signaling pathway. This disorder is characterized by p
Externí odkaz:
https://doaj.org/article/aa48d7ff5ed4437eaf168b646e9f35dd
Autor:
Deep Hathi, Arjun Baidya, Silima Subhasnigdha Tarenia, Niladri Das, Prashant Manohar Gaikwad, Yashaswi Pathak, Abhirup Banerjee, Mounam Chatterjee, Soumik goswami, Nilanjan Sengupta
Publikováno v:
Journal of the Endocrine Society. 6:A184-A185
Background Pseudohypoparathyroidism (PHP) is a heterogeneous group of disorders in which resistance to parathyroid hormone (PTH) in the proximal renal tubules leads to hypocalcemia, hyperphosphatemia, and impaired 1,25(OH)2 vitamin D production. Clin
Autor:
Niladri Das, Arjun Baidya, Silima Subhasnigdha Tarenia, Deep Hathi, Prashant Manohar Gaikwad, Yashaswi Pathak, Abhirup Banerjee, Mounam Chatterjee, Soumik Goswami, Nilanjan Sengupta
Publikováno v:
Journal of the Endocrine Society. 6:A519-A520
Introduction Rathke's cleft cysts (RCC) are cystic sellar and suprasellar lesion derived from remnant of Rathke's pouch. RCC are mainly asymptomatic, but can present with headache, visual disturbance, panhypopituitarism, hypothalamic dysfunction when
Autor:
ARJUN BAIDYA, YASHASWI PATHAK, NILANJAN SENGUPTA, PRANAB KUMAR SAHANA, SOUMIK GOSWAMI, SILIMA TARENIA, ABHIRUP BANERJEE, MOUNAM CHATTOPADHAYAY, DEEP HATHI, PRASHANT MANOHAR GAIKWAD, NILADRI DAS
Publikováno v:
Diabetes. 71
Aims: To study the effect of Vitamin D replacement on glycaemic control and pregnancy outcomes in Gestational Diabetes Mellitus patient with Vitamin D deficiency. Methods: In this prospective, open-label interventional study 60 GDM subjects with Vita